Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens

British Journal of Haematology

Volumn 166, Issue 6, 2014, Pages 842-848

  Mahmood, Shameem ^a   Venner, Christopher P ^a   Sachchithanantham, Sajitha ^a   Lane, Thirusha ^a   Rannigan, Lisa ^a   Foard, Darren ^a   Pinney, Jenny H ^a   Gibbs, Simon D J ^a   Whelan, Carol J ^a   Lachmann, Helen J ^a   Gillmore, Julian D ^a   Hawkins, Philip N ^a   Wechalekar, Ashutosh D ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Difference in involved and uninvolved free light chains; Haematological response; Lenalidomide; Monoclonal protein response; Overall survival

Indexed keywords

AMYLOID PROTEIN; ANTICOAGULANT AGENT; BORTEZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; THALIDOMIDE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOMODULATION; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MIDDLE AGED; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RASH; SEPSIS; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

DIFFERENCE IN INVOLVED AND UNINVOLVED FREE LIGHT CHAINS; HAEMATOLOGICAL RESPONSE; LENALIDOMIDE; MONOCLONAL PROTEIN RESPONSE; OVERALL SURVIVAL;

AGED; AMYLOIDOSIS; BORONIC ACIDS; COHORT STUDIES; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; HEMATOLOGIC AGENTS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; PARAPROTEINEMIAS; PYRAZINES; RECURRENCE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84907598117     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12973     Document Type: Article

References (22)

1. Bodin, K., Ellmerich, S., Kahan, M.C., Tennent, G.A., Loesch, A., Gilbertson, J.A., Hutchinson, W.A., Mangione, P.P., Gallimore, J.R., Millar, D.J., Minogue, S., Dhillon, A.P., Taylor, G.W., Bradwell, A.R., Petrie, A., Gillmore, J.D., Belotti, V., Botto, M., Hawkins, P.N. & Pepys, M.B. (2010) Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature, 468, 93-97.
2. Cibeira, M.T., Sanchorawala, V., Seldin, D.C., Quillen, K., Berk, J.L., Dember, L.M., Segal, A., Ruberg, F., Meier-Ewert, H., Andrea, N.T., Sloan, J.M., Finn, K.T., Doros, G., Blade, J. & Skinner, M. (2011) Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long term results in a series of 421 patients. Blood, 118, 4346-4352.
3. Comenzo, R.L., Reece, D., Palladini, G., Seldin, D., Sanchorawala, V., Landau, H., Falk, R., Wells, K., Solomon, A., Wechalekar, A., Zonder, J., Dispenzieri, A., Gertz, M., Streicher, H., Skinner, M., Kyle, R.A. & Merlini, G. (2012) Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain (AL) amyloidosis. Leukemia, 26, 2317-2325.
4. Dispenzieri, A., Lacy, M.Q., Zeldenrust, S.R., Hayman, S.R., Kumar, S.K., Geyer, S.M., Lust., J.A., Alfred, J.B., Witzig, T.E., Rajkumar, S.V., Greipp, P.R., Russell, S.J., Kabat, B. & Gertz, M.A. (2007) The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood, 109, 465-470.
5. Kastritis, E., Terpos, E., Roussou, M., Gavriatopoulou, M., Pamboukas, C., Boletis, I., Marinaki, S., Apostolou, T., Nikitas, N., Gkortzolidis, G., Michalis, E., Delimpasi, S. & Dimopoulos, M.A. (2012) A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood, 119, 5384-5390.
6. Kumar, S.K., Hayman, S.R., Buadi, F.K., Roy, V., Lacy, M.Q., Gertz, M.A., Alfred, J., Laumann, K.M., Bergsagel, L.P., Dingli, D., Mikhael, J.R., Reeder, C.B., Stewart, A.K., Zeldenrust, S.R., Greipp, P.R., Lust, J.A., Fonseca, R., Russell, S.J., Rajkumar, S.V. & Dispenzieri, A. (2012) Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood, 119, 4860-4867.
7. Lonial, S., Vij, R., Harousseau, J., Facon, T., Moreau, P., Mazumder, A., Kaufman, J.L., Leleu, X., Tsao, L.C., Westland, C., Singhal, A.K. & Jagannath, S. (2012) Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. Journal of Clinical Oncology, 30, 1953-1959.
8. Merlini, G. & Bellotti, V. (2003) Molecular mechanisms of amyloidosis. New England Journal of Medicine, 349, 583-596.
9. Moreau, P., Jaccard, A., Benboubker, L., Royer, B., Leleu, X., Bridoux, F., Salles, G., Leblond, V., Roussel, M., Alakl, M., Hermine, O., Planche, L., Harousseau, J. & Fernand, J. (2010) Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood, 116, 4777-4782.
10. Palladini, G., Russo, P., Foli, A., Milani, P., Lavatelli, F., Obici, L., Nuvolone, M., Brugnatelli, S., Invernizzi, R. & Merlini, G. (2012) Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Annals of Hematology, 91, 89-92.
11. Palladini, G., Russo, P., Milani, P., Foli, A., Lavatelli, F., Nuvolone, M., Perlini, S. & Merlini, G. (2013) A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica, 98, 433-436.
12. Palladini, G., Milani, P., Foli, A., Obici, L., Lavatelli, F., Nuvolone, M., Caccialanza, R., Perlini, S. & Merlini, G. (2014) Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica, 99, 743-750.
13. Pinney, J.H., Lachmann, H.J., Bansi, L., Wechalekar, A.D., Gilbertson, J.A., Rowczenio, D., Sattianayagam, P.T., Gibbs, S.D.J., Orlandi, E., Wassaf, N.L., Bradwell, A.R., Hawkins, P.N. & Gillmore, J.D. (2011) Outcome in Renal AL Amyloidosis after Chemotherapy. Journal of Clinical Oncology, 29, 674-681.
14. Sanchorawala, V., Wright, D.G., Rosenzweig, M., Finn, K.T., Fennessey, S., Zeldis, J.B., Skinner, M. & Seldin, D.C. (2007) Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood, 109, 492-496.
15. Sanchorawala, V., Finn, K.T., Fennessey, S., Shelton, A., Doros, G., Zeldis, J.B. & Seldin, D.C. (2010) Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood, 116, 1990-1991.
16. Sanchorawala, V., Shelton, A.C., Zeldis, J.B. & Seldin, D.C. (2013) Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide. American Journal of Hematology, 88, 719.
17. Specter, R., Sanchorawala, V., Seldin, D.C., Shelton, A., Fennessey, S., Finn, K.T., Zeldis, J.B. & Dember, L.M. (2011) Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrology Dialysis Transplantation, 26, 881-886.
18. Tapan, U., Seldin, D.C., Finn, K.T., Fennessey, S., Shelton, A., Zeldis, J.B. & Sanchorawala, V. (2010) Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood, 116, 5071-5072.
19. Wang, M., Dimopoulos, M., Chen, C., Cibeira, M.T., Attal, M., Spencer, A., Rajkumar, S.V., Yu, Z., Olesnyckyi, M., Zeldis, J.B., Knight, R.D. & Weber, D.M. (2008) Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardles of prior thalidomide exposure. Blood, 112, 4445-4451.
20. Wechalekar, A.D., Goodman, H.J., Lachmann, H.J., Offer, M., Hawkins, P.N. & Gillmore, J.D. (2007) Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood, 109, 457-464.
21. Wechalekar, A., Foard, D., Rannigan, L., Lane, T., Sachchitanatham, S., Mahmood, S., Sayed, R., Patel, K., Whelan, C., Lachmann, H., Hawkins, P.N. & Gillmore, J.D. (2014) Characteristics and outcomes of 714 patients with systemic AL amyloidosis - analysis of a prospective study (ALChemy study). In: Amyloid: Insoluble, but solvable. XIVth International Symposium on Amyloidosis, page 49, Abstract OP-31. http://www.amyloidosis.nl/indpls/XIVth%20International%20Symposium%20on%20Amyloidosis%20Book.pdf.
22. Wu, L., Parton, A., Lu, L., Adams, M., Schafer, P. & Bartlett, J.B. (2011) Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunology, Immunotherapy, 60, 61-73.